GlassScriptPhysician profile
Leroy Moore
NPI 1629032172
$2,867.37
in general payments reported to CMS, 2019-2025
25 companies · $94.67 in 2025
The $94.67 reported for 2025 was less than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2022: $1,220 · 2023: $1,183 · 2024: $132 · 2025: $94.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $639.95 | 2022-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $531.38 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.92 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $214.61 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $206.67 | 2021-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.84 | 2023 | Lifevest |
| Irhythm Technologies, INC. | $115.40 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Sanofi-Aventis U.S. LLC | $107.05 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $94.93 | 2021-2023 | Camzyos, Eliquis |
| Cvrx, INC. | $94.04 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $93.24 | 2022-2023 | Farxiga |
| Bridgebio Pharma, INC. | $58.42 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $43.17 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $34.20 | 2023 | |
| Kestra Medical Technology Services, INC. | $29.92 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G Medical Diagnostic Services, INC. | $27.66 | 2021-2022 | |
| Heartflow, INC. | $25.06 | 2023 | Ffrct |
| Atricure, INC. | $23.68 | 2021 | |
| Bardy Diagnostics, INC. | $20.00 | 2022 | |
| Pfizer INC. | $19.69 | 2022 | |
| Medicomp INC | $18.12 | 2023 | Telepatch Cardiac Monitor |
| Merck Sharp & Dohme LLC | $18.06 | 2025 | Verquvo |
| Baxter Healthcare | $16.97 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Tactile Systems Technology INC | $16.75 | 2022 | |
| Astellas Pharma US INC | $13.64 | 2023 | Lexiscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leroy Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.